Abstract: Inflammatory bowel disease (IBD) is a gastrointestinal disease that involves chronic mucosal or submucosal lesions that affect tissue integrity. Although IBD is not life-threatening, it sometimes causes severe complications, such as colon cancer. The exact etiology of IBD remains unclear, but several risk factors, such as pathogen infection, stress, diet, age, and genetics, have been involved in the occurrence and aggravation of IBD. Immune system malfunction with the over-production of inflammatory cytokines and associated oxidative stress are the hallmarks of IBD. Dietary intervention and medical treatment suppressing abnormal inflammation and oxidative stress are recommended as potential therapies. Thymol, a natural monoterpenoid phenol that is mostly found in thyme, exhibits multiple biological functions as a potential adjuvant for IBD. The purpose of this review is to summarize current findings on the protective effect of thymol on intestinal health in the context of specific animal models of IBD, describe the role of thymol in the modulation of inflammation, oxidative stress, and gut microbiota against gastrointestinal disease, and discuss the potential mechanism for its pharmacological activity.

Keywords: gastrointestinal disease; gut health; natural anti-oxidant; oxidative stress; chronic inflammation

1. Introduction

Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disorder of the gastrointestinal tract (GIT) [1]. It is not fatal, but imposes a burden on global healthcare and greatly reduces the quality of life of patients. From 1990 to 2017, the number of IBD patients increased from 37 million to more than 68 million, and the global prevalence of IBD increased by 85.1% [2]. The United States has the highest age-standardized prevalence rate in the world, accounting for nearly a quarter of all global IBD patients in 2017. Among European countries, the United Kingdom has the highest age-standardized prevalence. The prevalence of IBD in the United States ranges from 252 to 439 cases per 100,000 people [3]. Compared with western countries, the incidence of IBD in Asia is relatively low, but it has risen from 0.54 to 3.44 per 100,000 individuals across eight Asian countries [4,5]. The prevalence and incidence of IBD are continuing to increase worldwide in different races and countries [6].

IBD includes Crohn’s disease (CD) and ulcerative colitis (UC). UC involves long-lasting inflammation and ulcers along the superficial lining of the large intestine (rectum and colon), while CD is characterized by the discontinuous transmural inflammation in deeper layers of most regions of the GIT [7,8]. The exact cause of IBD remains unknown, but malfunction in the immune system is its hallmark. In IBD patients, an abnormal immune response to pathogen infection or stress causes chronic inflammation in the GIT contributing to the incidence of the disease [9]. Some genetic factors involved in an inappropriate immune response are a reason for IBD [10]. Oxidative stress (OS) with excessive accumulation
of reactive oxygen species (ROS) has been reported to correlate with intestinal chronic inflammation and incidence of IBD [11]. Moreover, alteration in the gut microbiota has been associated with the pathogenesis of IBD [12]. Unfortunately, there is currently no cure for IBD. Anti-inflammation medicines are used to relieve inflammation and even surgery is required to remove damaged parts of the GIT when patients suffer. Recently, advances in dietary regulation of inflammation, OS, and gut microbiota have resulted in dietary intervention against IBD incidence being recommended as a long-term prevention and therapy technique [13]. Currently, more research is focusing on natural plant extracts, such as phenol compounds, for the prevention and relief of IBD [14].

Thymol (2-isopropyl-5-methylphenol), a natural monoterpene phenol compound, is the major component of the essential oils extracted from plants of thyme species, such as *Thymus vulgaris*, *Coridothymus capitatus*, and *Origanum vulgare* [15]. Thymol exhibits multiple biological and pharmacological properties, including anti-inflammation, anti-oxidation, anti-bacteria, anti-fungal, and anti-tumor potential [16]. A high dose of thymol up to 500 mg/kg diet has been shown to have no toxicity [17]. Thus, thymol is considered as a beneficial food supplement. Recent studies reported that thymol improves intestinal integrity and alleviates intestinal injury via the regulation of the immune response and oxidation-reduction homeostasis [18]. In this review, we discussed the potential of thymol as a natural anti-inflammatory, anti-oxidative, and anti-bacterial compound in the modulation of mucosal immunity, OS, and gut microbes for IBD treatment.

### 2. Pharmacokinetics and Pharmacological Properties of Thymol

Thymol is the secondary metabolite produced by the aromatization of γ-terpinene to *p*-cymene, followed by the hydroxylation of *p*-cymene in plants [19] (Figure 1), including *Thymus zygis* [20], *Thymbra capitata* [21], *Thymus vulgaris* [22], *Satureja thymbra* [23], *Nigella sativa* seeds [24], and *Monarda didyma* [25]. Pure thymol has low solubility in water, high volatility, and a strong bitter/irritating taste [26]; thus, it is usually encapsulated in electrospun nanofibers to enhance its water solubility and high temperature stability [27]. Emulsification is also used for thymol processing. Both encapsulation and emulsification have been shown to improve the anti-oxidant activity of thymol [28].

![Thymol biosynthesis](image)

**Figure 1.** Thymol biosynthesis in plants. Thymol is synthesized by the hydroxylation of *p*-cymene, which originates from the aromatization of γ-terpinene.

Thymol administered orally can be rapidly absorbed in the stomach and small intestines, and then transported to various organs via the circulation system in animals [29]. Thymol can be metabolized to thymol sulfate and thymol glucuronide by sulfation and glucuronidation in the intestines, liver, kidney, and other organs, respectively [30]. Thymol and its metabolites reach the maximum concentration in the blood 30 min after oral administration and then are slowly eliminated in about 24 h [26]. They also present in the lungs, kidneys, mucosa of the small and large intestines, and other organs, suggesting that they may function directly in these organs. It is difficult to determine which compound is the
active form of thymol, because thymol metabolites can be deconjugated to thymol locally and export its pharmacological activity in this way [31]. Recently, scientists have focused on the pharmacological activities of thymol.

Thymol-containing plants have long been used in traditional Chinese medicine due to its pharmacological properties. Thymol acts as a potent inhibitor of the release of inflammatory cytokines, such as interleukin (IL)-6, IL-1β, and IL-8 [32]. Thymol enhances anti-oxidative capacity to alleviate OS in different tissues [33]. As a spectrum anti-bacterial agent, thymol reduces the activities of microorganisms belonging to the Enterobacteriaceae, Streptococcus, and Saccharomycetaceae families, involving membrane rupture, inhibition of biofilm formation, and other pathways [34,35]. Thymol shows anti-viral potential to inhibit virus colonization, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), by docking with the S1 receptor-binding domain of spike glycoprotein [36]. Thymol also exhibits other pharmacological functions, such as analgesia, anti-malarial, and anti-fungal properties [37–41]. This review focuses on the therapeuic potential of thymol in IBD in terms of its pharmacological properties and discusses the underlying mechanisms.

3. Thymol Protects Intestinal Barrier Function against IBD

The intestinal barrier, mainly composed of intestinal epithelial cells (IECs) and immune cells, maintains the balance between the luminal contents and mucosa. The disturbance of this balance has been associated with gastrointestinal diseases, such as IBD [42]. Although the exact pathogenesis of IBD remains unclear, a “leaky gut” with impaired intestinal barrier function is the main feature. The intestinal barrier is the first line of defense against pathogen infection, and injury to the intestinal barrier aggravates the disease. Thus, understanding how thymol protects the intestinal barrier is important for relieving IBD.

Thymol has exhibited a protective function for the intestinal barrier in both in vivo and in vitro studies, as illustrated in Table 1, and its specific mechanism is shown in Figure 2. Thymol attenuates weaning stress-induced diarrheal and intestinal barrier dysfunction in weanling pigs by reducing the serum diamine oxidase level, an indicator of intestinal integrity, and increasing the expression of the tight junction protein zonula occludens-1 (ZO-1) and occludins [43]. Thymol alleviates dextran sulfate sodium (DSS)-induced intestinal damage and increases tight junction claudin-3 expression [44]. Increased plasma endotoxin and D-lactic acid levels are markers of increased intestinal permeability. The latest study found that dietary thymol reduced the plasma endotoxin and D-lactic acid concentrations on days 7 and 14 post-weaning [45]. The intestinal mucus layer is the first line of defense maintaining bacterial symbiosis with the host and preventing bacterial penetration into epithelial cells [46]. Thymol increases mucus secretion to relieve ethanol-induced ulcer mucosal damage in rats [47]. In IPEC-J2 cells, thymol alleviates lipopolysaccharide (LPS)-induced decrease in trans-epithelial electrical resistance (TEER), indicating an increase in the integrity of the single cell layer [48]. In Caco-2 cells, thymol increases the integrity of the tight junction and up-regulates cyclooxygenase-1 (COX1) activity to maintain GIT homeostasis, which is beneficial for intestinal health [49]. In addition, thymol changes the expressions of 120 and 59 genes in the oxyntic and pyloric mucosa, respectively, which are associated with gastric epithelium proliferation and maturation activities in weaned pigs [29].
Table 1. Protective function of thymol on the intestinal barrier.

| Model                              | Thymol Dose | Effects                                                                 | Ref.  |
|------------------------------------|-------------|-------------------------------------------------------------------------|-------|
| In vivo                            |             |                                                                         |       |
| Weaned pigs                        | 50 mg/kg diet | Enrichment of 120 and 59 gene sets in oxyntic and pyloric mucosa↓       | [29]  |
| Ethanol-induced acute ulcer        | 10–100 mg/kg diet | Mucosal damage↓                                                         | [47]  |
| Chicken infected with Clostridium perfringens | 30 mg/kg diet | Intestinal lesions and mortality↓ Lactobacillus salivarius and L. johnsonii↓ L. crispatus, L. agilis, and Escherichia coli↑ Expression of ZO-1 and occludins in jejunal mucosa↓ Enterococcus genus and E. coli↓ Plasma diamine oxidase concentration↓ Weaning-induced intestinal OS↓ | [50]  |
| Weaned pigs                        | 100 mg/kg diet | Expression of ZO-1 and occludins in jejunal mucosa↓                     | [43]  |
| In vitro                           |             |                                                                         |       |
| IPEC-J2                            | 50 µM       | TEER↑ Cell permeability↓ ZO-1 and actin staining↑ COX1 transcription↑ TEER↑ | [48]  |
| Caco-2 cells                       | 15 mg/L     | COX1:COX2 ratio↑                                                         | [49]  |

↑ indicates for rising; ↓ indicates for descending.

Figure 2. Action of thymol to protect intestinal barrier function. Pathogen infection in the intestinal lumen reduces mucus secretion and the expressions of tight junction proteins, and increases intestinal permeability, resulting in a “leaky gut”, which increases the risk of intestinal disease. Thymol has been shown to defend against pathogen invasion, promote mucus secretion, and enhance intestinal barrier integrity.

4. Thymol Alleviates Intestinal Inflammation in IBD

The dysregulation of innate and adaptive immune responses leads to chronic intestinal inflammation in IBD patients [51–53]. Transcription factor nuclear factor κB (NF-κB) is the key mediator regulating the inflammatory response. The activation of NF-κB signaling induces the expression of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), interleukin (IL-1β), and IL-6 [54]. The
over-production and accumulation of inflammatory cytokines cause intestinal epithelial apoptosis and the disruption of intestinal homeostasis, resulting in the dysfunction of the intestinal epithelial barrier in IBD patients [55]. Currently, the suppression of inflammation is the mainstay of IBD treatment.

Thymol shows strong anti-inflammatory properties in in vivo and in vitro studies [56]. The anti-inflammatory properties of thymol are listed in Table 2 and a schematic diagram of thymol’s action is depicted in Figure 3. Toll-like receptors (TLRs) are the main sensors used to detect various dangerous signals and activate innate immune responses. The classic TLR signaling pathway activates NF-κB to regulate the expressions of a series of cytokines [57]. In mice and macrophages, thymol inhibits TLR4 expression and then inhibits the activation of NF-κB signaling, which reduces the production of inflammatory cytokines, such as TNF-α and IL-1β [58,59]. NF-κB is a master mediator of inflammatory responses. Inactive NF-κB binds to IkB, an inhibitory subunit of NF-κB, and presents in the cytoplasm. When activated by a variety of signals, such as cytokine receptors and pattern-recognition receptors (PRRs), IkB is phosphorylated and degraded to release RelA (p65) from the NF-κB complex. p65 is then translocated to the nucleus to induce pro-inflammatory cytokine expression as a transcription factor [60]. Thymol has been shown to inhibit NF-κB activation by reducing p65 translocation and abundance in the colons of acetic acid-induced colitis rats and in LPS-activated macrophages, respectively, with decreased cytokine production [61,62]. The activation of NF-κB induces the expressions of iNOS and COX-2, which further promote vigorous inflammation. In ulcerative colitis rats, thymol reduces the COX-2 expression and nitric oxide (NO) levels produced by iNOS in the rats’ colon [63]. These studies showed the anti-inflammatory function of thymol through the inhibition of the NF-κB signaling pathway.

Table 2. Summary of the effect of thymol in different inflammation models.

| Model                                      | Thymol Dose          | Effects                                      | Ref. |
|--------------------------------------------|----------------------|----------------------------------------------|------|
| **In vitro**                               |                      |                                              |      |
| Mouse macrophages challenged with LPS      | 20 mg/mL             | IL-1β expression↓                           | [59] |
| Mouse mammary epithelial cells challenged with LPS | 10–40 µg/mL          | TNF-α, IL-6, iNOS, and COX-2 expression↓, Phosphorylation of IkBα, NF-κBp65↓. | [64] |
| Human peritoneal mesothelial cell line challenged with LPS | 10–40 µg/mL          | NF-κB p65, IkK, and IkBα phosphorylation↓, TNF-α, IL-6 expression↓. | [65] |
| IPEC-J2 cells challenged with LPS          | 10–100 µM            | IL-8 secretion↓, TLR4 is inhibited           | [66] |
| Chitin-induced airway epithelial cells     | 30 µg/mL             | IL-25 and IL-33 release↓                    | [67] |
| HaCaT cells challenged with *Staphylococcus aureus* | 512 µg/mL            | IL-1β, IL-6, and IL-8 expression↓, Phosphorylation of p65 and IkBα↓. | [68] |
| **In vivo**                                |                      |                                              |      |
| DSS-induced mouse colitis                  | 30–60 mg/kg diet     | NO, TNF-α, IL-1β, IL-6 expression↓, Phosphorylation of IkBα and NF-κBp65↓. | [62] |
| Indomethacin-induced rat gastric ulcer     | 75–500 mg/kg diet    | TNF-α, iNOS levels↓                         | [17] |
| Indomethacin-induced rat gastric ulcer     | 50–500 mg/kg diet    | ROS, eNOS, TNF-α, caspase-3 levels↓, Prostaglandin E2 (PGE2) levels↑, COX-2, IL-6, IL-1β and TNF-α expression↓, mRNA level of NF-κB p65↓, Myeloperoxidase (MPO) activity, NO, and malondialdehyde (MDA) level↓. | [69] |
| Rat ulcerative colitis                     | 100 mg/kg diet       | Plasma IL-5, IL-13, IgE levels↓, TNF-α expression in the nasal mucosa of rats↓. | [63] |
| Ovalbumin-induced rat allergic rhinitis    | 20 mg/kg diet        | TLR2 and TNF-α level in ileum↓              | [18] |

↑ indicates for rising; ↓ indicates for descending.
Figure 3. Mechanism of thymol in relieving inflammation. Cells receive various stimuli and activate IkB kinases (IkKs) through the TLR4 signaling pathway, and then IkB proteins are phosphorylated, ubiquitinated, and degraded, and NF-κB dimers are released. The NF-κB dimer is then further activated through various post-translational modifications and translocated into the nucleus to bind to target genes to promote pro-inflammatory gene transcription. In addition, by activating the MAPKs family, it can promote the expression of c-jun terminal kinases (JNK) 1/2, extracellular signal-regulated kinase (ERK), and p38 for activation, thereby promoting the nuclear entry of activator protein 1 (AP-1) to regulate the expression of pro-inflammatory genes. Thymol inhibits the dissociation of the IkB protein and NF-κB dimer and the activation of the mitogen-activated protein kinase (MAPK) signaling pathway to relieve inflammation.

Studies have reported that proteins in the MAPK family, such as JNK1/2, p38α, and ERK, are activated in the colonic mucosa of IBD patients [71]. The suppression of the MAPK signaling pathway is an approach for alleviating inflammation and thus IBD [71]. It has been reported that thymol inhibits p38 phosphorylation and interferes with the activation of the MAPK signaling pathway to maintain the immune balance [64]. Thymol also suppresses LPS-induced activation of p-p38, p-JNK, and p-ERK, and correspondingly inhibits the production of NO, IL-6, TNF-α, COX-2, and other inflammatory cytokines [72]. Therefore, thymol can also reduce the inflammatory response by inhibiting the MAPK signaling pathway.

Cytokines are synthesized and secreted by activated immune cells, such as macrophages, T cells, B cells, dendritic cells (DCs), and natural killer cells. Among them, the regulatory T cell (Treg) is essential to control autoimmunity. Treg is defined by the expression of CD4, CD25, and transcription factor forkhead box P3 (Foxp3) [73]. Thymol promotes the differentiation of naïve T cells to CD4+CD25+Foxp3+ Treg cells and induces Foxp3 expression [74]. Meanwhile, thymol also maintains the balance of the Th1/Tregs and Th17/Tregs ratios to prevent autoimmunity as a result of suppressed inflammation [74,75]. Additionally, thymol exerts inhibitory effects on DCs’ maturation and T cell activation [76]. Although thymol has influenced the immune cell population in some studies, more information is required
on how thymol modulates immune cell differentiation and whether the changes in the immune cell population by thymol contribute to the relief of IBD.

5. Thymol Improves Anti-Oxidant Capacity in IBD

IBD has been also associated with intestinal OS [77]. OS is the result of the excessive accumulation of ROS caused by the imbalance of the oxidation and anti-oxidation systems in cells [78]. Generally, ROS include hydrogen peroxide (H$_2$O$_2$), superoxide anions (O$_2^{-}$), and hydroxyl radicals (HO·). The accumulation of ROS alters the structure and function of cell contents, such as DNA and proteins, and causes a series of cellular dysfunctions, including the disruption of cell metabolism, disruption of cell cycles, dysregulation of the immune response, etc. In IBD patients, the overproduction of ROS destroys the cytoskeleton and interrupts tight junction proteins in the intestinal epithelium, resulting in increased epithelial permeability and intestinal barrier dysfunction [79]. In addition, OS has been reported to be positively correlated with the level of inflammation [80], and OS in the GIT exacerbates intestinal inflammation and IBD. Therefore, the relief of intestinal OS is another strategy for treating IBD [81].

Thymol has been shown to have anti-oxidative capacity in a variety of OS models in vitro and in vivo, as listed in Table 3. A schematic mechanism of thymol’s action is depicted in Figure 4. Thymol acts as a strong anti-oxidant, partially due to its phenolic hydroxyl groups, which directly neutralize free radicals [82]. 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS$^+$) are commonly used free radicals to evaluate anti-oxidant activity. Thymol eliminates 50% of DPPH radicals and scavenges ABTS$^+$ radicals as a direct anti-oxidant in vitro [83]. However, other studies have indicated that phenolic compounds exert an anti-oxidative function through the activation of anti-oxidation-related signaling pathways, rather than directly neutralizing free radicals by the phenolic hydroxyl group [84]. Studies indicated that dietary polyphenols activate the anti-oxidation-related nuclear factor-E2-related factor 2 (Nrf2) signaling pathway, which plays a pivotal role in regulating the expression of anti-oxidant genes and the activities of anti-oxidant enzymes [85]. Studies have indicated that thymol activates Nrf2 signaling in different tissues [86,87]. Importantly, the Nrf2 downstream target HO-1 catalyzes the degradation of heme into Fe$^{2+}$, CO, and bilirubin. Heme enhances ROS formation in OS, while bilirubin is an anti-oxidant and protects tissues [88]. Thymol promotes HO-1 expression in the lungs of mice, accounting for its anti-oxidative capacity [87]. Moreover, HO-1-induced CO also performs anti-inflammation and anti-apoptosis functions, which support the mechanism of thymol alleviating inflammation and intestinal damage.

Table 3. Anti-oxidant properties of thymol.

| Model                                              | Thymol Dose       | Response                                      | Ref. |
|----------------------------------------------------|-------------------|-----------------------------------------------|------|
| **In vitro**                                       |                   |                                               |      |
| Tert-butyl hydroperoxide-induced OS in Chang cells | 12.5–50 µg/mL     | ROS generation and MDA level↓, Glutathione (GSH) level↑ | [89] |
| Radiation-induced cytotoxicity in lung fibroblast (V79) cells | 0–100 µg/mL     | Radiation-induced lipid peroxidation↓, GSH, catalase (CAT), and superoxide dismutase (SOD)↑ | [90] |
| Chinese hamster lung fibroblast cells (V79) Candida albicans | 0–100 µg/mL 5–20 µg/mL | Radiation-induced genotoxicity and apoptosis↓, Activity of CAT, glutathione peroxidase (GPX)↑ | [91] [92] |
| **In vivo**                                        |                   |                                               |      |
| Imidacloprid-induced testicular toxicity          | 30 mg/kg diet     | CAT, SOD, and GSH↑                           | [93] |
| L-arginine-induced acute pancreatitis             | 50–100 mg/kg diet | MPO and O$_2^{-}$↓                          | [94] |
Table 3. Cont.

| Model                                      | Thymol Dose | SOD and CAT activity in serum↑ | Ref. |
|--------------------------------------------|-------------|--------------------------------|------|
| High fat diet-induced obesity in mice      | 14 mg/kg diet | MDA level in serum↓          | [95] |
| Ovalbumin-induced asthma in mice           | 8–32 mg/kg diet | MDA level↓                  | [39] |
| Wistar rats                                | 42.5 mg/kg diet | GSH-Px activity↑            | [96] |
| Rats                                       | 10–20 mg/kg diet | Brain total anti-oxidant status↑ | [97] |
| Cisplatin-induced nephrotoxicity in rats   | 20 mg/kg diet | GSH, SOD, and CAT levels in kidney↑ | [98] |

↑ indicates for rising; ↓ indicates for descending.

Figure 4. Mechanism of thymol scavenging free radicals. XO catalyzes the oxidation of xanthine and hypoxanthine with increased production of O$_2^-$ in purine metabolism or O$_2^-$ is generated in the mitochondrial inner membrane through the respiratory electron transport chain. The former enters the peroxisome and the latter is catalyzed by SOD in the mitochondria to generate H$_2$O$_2$. CAT and GPX in the peroxisome catalyze H$_2$O$_2$ to generate H$_2$O and O$_2$ and H$_2$O$_2$ in the cytoplasm is affected by Fe$^{2+}$ to generate OH$^-$. Elevated levels of free radicals can lead to oxidative stress. Thymol reduces ROS by directly scavenging free radicals, combining with XO, or increasing anti-oxidant enzyme activity.

Nrf2 maintains the cellular redox balance and prevents oxidative damage by regulating anti-oxidant enzymes, such as GSH and GPX. As a result, thymol increases the activities of anti-oxidant enzymes to reduce ROS production. SOD reduces superoxide O$_2^-$ radicals by catalyzing them into O$_2$ and H$_2$O$_2$. H$_2$O$_2$ is then transformed by either CAT or GPX in the peroxisome to generate water and O$_2$. Thymol enhances the activities of anti-oxidant enzymes and alleviates OS in animal models of OS [89]. Thymol enhances the total anti-oxidative capacity and reduces the ROS level in rats challenged with imidacloprid [93]. Thymol reduces the MDA level, a byproduct of lipid peroxidation and a marker of OS, increases SOD activity, and ameliorates OS in mouse obesity models [95]. In vitro studies, thymol ameliorates acetaminophen-induced OS in HepG2 cells by increasing the GPX and SOD activities and decreasing the MDA level [99]. In lung fibroblasts, thymol increases the enzyme activities of SOD, CAT, and GPX, leading to a reduction in ROS production [90]. In the Chang liver cell line, thymol inhibits ROS production by increasing the GPX level and decreasing the MDA level, alleviating t-butyl-hydroperoxide-induced oxidative damage.
In addition to the aforementioned anti-oxidant enzymes, thymol reduces OS through the inhibition of free-radical-generating enzyme xanthine oxidase (XO) [100]. XO catalyzes the oxidation of xanthine and hypoxanthine with increased production of $\text{O}_2^-$ and $\text{H}_2\text{O}_2$ in purine metabolism [101]. Thymol binds to XO directly and inhibits XO activity to produce ROS [100]. Collectively, thymol relieves OS via directly scavenging free radicals by its phenolic hydroxyl group, directly inhibiting free-radical-producing enzymes, and indirectly activating the Nrf2-mediated signaling pathway.

6. Thymol Changes Gut Microbes and Prevents Pathogen Infection

Mammalian gut microbes are mainly composed of four phyla, including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Alterations in the gut microbiota are observed in patients with IBD compared with healthy individuals. Notably, the abundance of the phylum Firmicutes is reduced in the stool of UC patients [102]. Although there is a lack of clinical research about the thymol-modulated gut microbial structure in IBD, multiple animal studies have described increases in the proportional abundance of Firmicutes potentially against IBD pathogenesis due to thymol [103]. However, a direct causative relationship between IBD and dysbiosis has not been clearly established in humans. The change in gut microbes by thymol as a therapeutical mechanism requires more elucidative studies.

Currently, studies of the microbial etiology of IBD indicate that persistent pathogen infection, such as enterotoxigenic $\text{E}. \text{coli}$, causes a “leaky gut” and chronic inflammation, subsequently leading to the excessive translocation of intestinal bacteria and the dysbiosis between “beneficial” and “detrimental” bacteria, resulting in IBD [104]. The members of the Proteobacteria phylum, notably the Enterobacteriaceae $\text{E}. \text{coli}$, are increased in IBD patients relative to healthy individuals [105]. Several studies have indicated the anti-pathogen capacity of thymol in different animal infection models and bacterial cultures, as illustrated in Table 4, as the potential mechanism. Researchers found that thymol reduces the abundance of the detrimental bacteria $\text{E}. \text{coli}$ in the GIT of pigs [43]. In another study, feeding pigs with microencapsulated thymol promoted the proliferation of beneficial bacteria in the colon and decreased the colonization of detrimental bacteria, such as Escherichia, Campylobacter, Treponema, and Streptococcus [106]. In chickens infected with $\text{C. perfringens}$, thymol inhibited $\text{C. perfringens}$ proliferation and then alleviated intestinal damage and mortality [50]. In these studies, thymol also promoted the colonization of beneficial bacteria, such as Clostridium, Lactobacillus, and Bacteroides, to improve gut health. Additionally, thymol also exhibited a direct anti-bacterial effect inhibiting human pathogens, such as $\text{E}. \text{coli}$, $\text{L. monocytogenes}$, and $\text{C. perfringens}$, which are harmful to the body’s health [107–110].

Table 4. Thymol prevents pathogen infection.

| Model                | Thymol Dose          | Effects                                      | Ref.   |
|----------------------|----------------------|----------------------------------------------|--------|
| In vivo              |                      |                                              |        |
| Weaning pigs         | 2% thymol diet       | Colon probiotic bacteria↑ Potential pathogens↓ Clostridium, Bacteroides, Lactobacillus↑ Proteobacteria↓ | [106]  |
| Cobb broilers        | 150 mg/kg diet       |                                              | [111]  |
|                      |                      |                                              |        |
| Pathogen culture medium |                |                                              |        |
| Ground chicken       | 100–200 ppm          | $\text{E. coli}$ O157:H7↓ | [108]  |
| Meat medium          | 46.875–6000 µg/mL    | $\text{E. coli}$, $\text{Salmonella}$, and $\text{C. perfringens}$↓ | [107]  |
| Apple cider and milk | 0.5 g/L              | $\text{E. coli}$ O157:H7 and $\text{L. monocytogenes}$↓ | [109]  |
| Cattle waste         | 6.7 mM               | Fecal coliforms↓                            | [110]  |

↑ indicates for rising; ↓ indicates for descending.
Overall, thyme exhibits therapeutic potential to treat IBD through multiple mechanisms, including the intestinal barrier, inflammation, redox homeostasis, and gut microbiota. The deregulation of any one aspect influences others, which also renders IBD a complex and multifactor disease. As mentioned, a compromised gut barrier leads to the invasion of pathogens, leading to an imbalance in the gut microbiota and the activation of an immune response; uncontrolled inflammation causes enterocyte death and further aggravates intestine damage. Moreover, prolonged inflammation also leads to the accumulation of free radicals and imbalance of redox homeostasis, which exacerbate inflammation. Therefore, it is difficult to conclude which mechanism plays a pivotal role in mediating thymol action unless a dedicated molecular mechanism is illustrated.

7. Conclusions

Multiple factors, including the environment, microorganisms, and genetics, interact to promote the development and occurrence of IBD [112]. Environmental factors, such as diet, which lead to gut microbiota dysbiosis, alter host mucosal defenses, and induce intestinal OS, are deemed to be major potential risk factors for IBD [113]. Simultaneously, diet is also a double-edged sword that is beneficial to the prevention and relief of IBD. More recently, green tea polyphenols have been shown to benefit IBD patients by reversing gut dysbiosis [114]. Therefore, nutritional intervention should be further promoted as a low-cost, side-effect-free method for the prevention and treatment of IBD [115]. Thymol, a natural product derived from medicinal plants or herbs, is commonly used as a dietary supplement to prevent IBD by improving gut integrity, reducing gut OS, and modulating gut immune responses. In addition, thymol maintains a good intestinal microenvironment through its anti-bacterial properties. Currently, considering that the common drugs used for IBD, such as corticosteroids, mesalazine, and balasaladin, have relatively large side effects, herbal plant extracts, such as thymol, as natural anti-oxidants may represent promising substances in the complementary therapy of IBD, with special emphasis on prevention. However, there are still doubts regarding how thymol regulates mucosal immunity and the mechanism of treating IBD by improving OS in the intestinal tract. Meanwhile, there have been no clinical trials yet, so an effective method and dosage for people ingesting thymol need to be further studied. In conclusion, considering the health benefits of thymol and its non-toxicity, thymol is a potential drug and rational strategy for the relief of IBD.

Author Contributions: Writing—original draft preparation, Y.L. (Yao Liu) and H.Y.; writing—review and editing, B.Y., J.H., X.M., J.Y. and P.Z.; visualization, Z.H., Y.L. (Yuheng Luo), J.L. and A.W.; supervision and conceptualization, H.Y. and D.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Sichuan Science and Technology Program under grants (2021Y0195, 2021ZDZX0009), the National Key Research and Development Program of China (2021YFD1300201), and the China Agriculture Research System of MOF and MARA (CARS-35).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: There is no conflict of interest to declare.

References
1. Duerr, R.H.; Taylor, K.D.; Brant, S.R.; Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; Abraham, C.; Regueiro, M.; Griffiths, A.; et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314, 1461–1463. [CrossRef] [PubMed]
2. Sudabeh Alatab, S.G.S. Kevin Ikuta, Homayoon Vahedi, Catherine Bisignano. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020, 5, 17–30.
3. Kaser, A.; Zeissig, S.; Blumberg, R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28, 573–621. [CrossRef] [PubMed]
4. Loftus, E.V., Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004, 126, 1504–1517. [CrossRef]

5. Ng, S.C. Epidemiology of inflammatory bowel disease: Focus on Asia. *Best Pract. Res. Clin. Gastroenterol.* 2014, 28, 363–372. [CrossRef] [PubMed]

6. Kaplan, G.G.; Ng, S.C. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* 2017, 152, 313–321. [CrossRef]

7. Corridoni, D.; Arseneau, K.O.; Cominelli, F. Inflammatory bowel disease. *Immunol. Lett.* 2014, 161, 231–235. [CrossRef]

8. Wallfish, A.; Sachar, D. Phenotype classification in IBD: Is there an impact on therapy? *Inflamm. Bowel Dis.* 2007, 13, 1573–1575. [CrossRef]

9. Geremia, A.; Biancheri, P.; Allan, P.; Corazza, G.R.; Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. *Autoimmun. Rev.* 2014, 13, 3–10. [CrossRef]

10. Van Limbergen, J.; Russell, R.K.; Nimmo, E.R.; Satsangi, J. The genetics of inflammatory bowel disease. *Am. J. Gastroenterol.* 2007, 102, 2820–2831. [CrossRef]

11. Zhao, Y.; Guo, Q.; Zhu, Q.; Tan, R.; Bai, D.; Bu, X.; Lin, B.; Zhao, K.; Pan, C.; Chen, H.; et al. Flavonoid VI-16 protects against stress. *Mucosal Immunol.* 2019, 12, 1150–1163. [CrossRef] [PubMed]

12. Matsuoka, K.; Kanai, T. The gut microbiota and inflammatory bowel disease. *Semin. Immunopathol.* 2015, 37, 47–55. [CrossRef] [PubMed]

13. Lee, D.; Albenberg, L.; Compher, C.; Baldassano, R.; Piccoli, D.; Lewis, J.D.; Wu, G.D. Diet in the pathogenesis and treatment of inflammatory bowel diseases. *Gastroenterology* 2015, 148, 1087–1106. [CrossRef]

14. Martin, D.A.; Bolling, B.W. A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases. *Food Funct.* 2016, 7, 1773–1786. [CrossRef]

15. Hazzit, M.; Baaiouamer, A.; Faleiro, M.L.; Miguel, M.G. Composition of the essential oils of Thymus and Origanum species from Algeria and their antioxidant and antimicrobial activities. *J. Agric. Food Chem.* 2006, 54, 6314–6321. [CrossRef] [PubMed]

16. Salehi, B.; Mishra, A.P.; Shukla, I.; Sharifi-Rad, M.; Contreras, M.D.M.; Segura-Carretero, A.; Fathi, H.; Nasrabad, N.N.; Kobafard, F.; Sharifi-Rad, J. Thymol, thyme, and other plant sources: Health and potential uses. *Phytother. Res.* 2018, 32, 1688–1706. [CrossRef]

17. Geyikoglu, F.; Yilmaz, E.G.; Erol, H.S.; Koc, K.; Cerig, S.; Ozek, N.S.; Aysin, F. Hepatoprotective Role of Thymol in Drug-Induced Gastric Ulcer Model. *Ann. Hepatol.* 2018, 17, 980–991. [CrossRef]

18. Du, E.; Wang, W.; Gan, L.; Li, Z.; Guo, S.; Guo, Y. Effects of thymol and carvacrol supplementation on intestinal integrity and immune responses of broiler chickens challenged with Clostridium perfringens. *J. Anim. Sci. Biotechnol.* 2016, 7, 19. [CrossRef]

19. Poulase, A.J.; Croteau, R. Biosynthesis of aromatic monoterpenes: Conversion of gamma-terpinene to p-cymene and thymol in *Thymus vulgaris* L. *Arch. Biochem. Biophys.* 1978, 187, 307–314. [CrossRef]

20. Ocaña, A.; Reglero, G. Effects of Thyme Extract Oils (from *Thymus vulgaris*, *T. zygis*, and *T. hyemalis*) on Cytokine Production and Gene Expression of oxLDL-Stimulated THP-1-Macrophages. *J. Obes.* 2012, 2012, 104706. [CrossRef]

21. Machado, M.; Dinis, A.M.; Salgueiro, L.; Cavaleiro, C.; Custódio, J.B.; Sousa Mdo, C. Anti-Giardia activity of phenolic-rich essential oils: Effects of *Thymbra capitata*, *Origanum virens*, *T. cyaneus* subsp. *sylvestris*, and *Lippia graveolens* on trophozoites growth, viability, adherence, and ultrastructure. *Parasitol. Res.* 2010, 106, 1205–1215. [CrossRef]

22. Nikolić, M.; Glamočlija, J.; Ferreira, I.C.F.R.; Calhelha, R.C.; Fernandes, A.; Marković, T.; Marković, D.; Giweli, A.; Soković, M. Chemical composition, antimicrobial, antioxidant and antitumor activity of *Thymus serpyllum* L., *Thymus algeriensis* Boiss. and *Reut* and *Thymus vulgaris* L. essential oils. *Ind. Crops Prod.* 2014, 52, 183–190. [CrossRef]

23. Karousou, R.; Koureas, D.N.; Kokkini, S. Essential oil composition is related to the natural habitats: *Coridothymus capitatus* and *Satureja thymbra* in NATURA 2000 sites of Crete. *Phytochemistry* 2005, 66, 2668–2673. [CrossRef] [PubMed]

24. Maulidiana, M.; Sheikh, B.Y.; Mediani, A.; Wei, L.S.; Imsai, I.S.; Abas, F.; Laijs, N.H. Differentiation of Nigella sativa seeds from four different origins and their bioactivity correlations based on NMR-metabolomics approach. *Phytochem. Lett.* 2015, 13, 308–318. [CrossRef]

25. Laquale, S.; Avato, P.; Argentieri, M.P.; Bellardi, M.G.; D’Addabbo, T. Nematotoxic activity of essential oils from *Monarda* species. *J. Pest Sci.* 2018, 91, 1115–1125. [CrossRef]

26. Nieddu, M.; Rassu, G.; Boatto, G.; Bosi, P.; Trevisi, P.; Giunchedi, P.; Carta, A.; Gavini, E. Improvement of thymol properties by complexation with cyclodextrins: In vitro and in vivo studies. *Carbohydr. Polym.* 2014, 102, 393–399. [CrossRef]

27. Celebioglu, A.; Yildiz, Z.I.; Uyar, T. Thymol and cycloexodrin inclusion complex nonfibrous webs: Enhanced water solubility, high thermal stability and antioxidant property of thymol. *Food Res. Int.* 2018, 106, 280–290. [CrossRef] [PubMed]

28. Sedaghat Doost, A.; Van Camp, J.; Dewettinck, K.; Van der Meeren, P. Production of thymol nanoemulsions stabilized using Quillaja Saponin as a biosurfactant: Antioxidant activity enhancement. *Food Chem.* 2019, 293, 134–143. [CrossRef]

29. Colombo, M.; Priori, D.; Gandolfi, G.; Boatto, G.; Nieddu, M.; Bosi, P.; Trevisi, P. Effect of free thymol on differential gene expression in gastric mucosa of the young pig. *Animal* 2014, 8, 786–791. [CrossRef]

30. Písarcíková, J.; Oceľová, V.; Faix, Š.; Plachá, I.; Calderón, A.I. Identification and quantification of thymol metabolites in plasma, liver and duodenal wall of broiler chickens using UHPLC-ESI-QTOF-MS. *Biomed. Chromatogr.* 2017, 31, e3881. [CrossRef]
31. Lugarà, R.; Grzeskowiak, L.; Zentek, J.; Meese, S.; Kreuzer, M.; Giller, K. A High-Energy Diet and Spirulina Supplementation during Pre-Gestation, Gestation, and Lactation do Not Affect the Reproductive and Lactational Performance of Primiparous Sows. *Animals* 2022, 12, 1171. [CrossRef] [PubMed]

32. Pandur, E.; Micalizzi, G.; Mondello, L.; Horvath, A.; Sipos, K.; Horvath, G. Antioxidant and Anti-Inflammatory Effects of Thyme (*Thymus vulgaris* L.) Essential Oils Prepared at Different Plant Phenophases on Pseudomonas aeruginosa LPS-Activated THP-1 Macrophages. *Antioxidants* 2022, 11, 1330. [CrossRef]

33. Ahmmed, O.M.; Galal, S.R.; Mostafa, M.M.A.; Eed, E.M.; Ali, T.M.; Fahmy, A.M.; Zaky, M.Y. Thyme Oil and Thymol Counter Doxorubicin-Induced Hepatotoxicity via Modulation of Inflammation, Apoptosis, and Oxidative Stress. *Oxid. Med. Cell. Longev.* 2022, 2022, 6702773. [CrossRef]

34. Yin, L.; Liang, C.; Wei, W.; Huang, S.; Ren, Y.; Geng, Y.; Huang, X.; Chen, D.; Guo, H.; Fang, J.; et al. The Antibacterial Activity of Thymol Against Drug-Resistant *Streptococcus iniae* and Its Protective Effect on Channel Catfish (*Ictalurus punctatus*). *Front. Microbiol.* 2022, 13, 914868. [CrossRef] [PubMed]

35. Yao, Z.; Feng, L.; Zhao, Y.; Zhang, X.; Chen, L.; Wang, L.; Zhang, Y.; Sun, Y.; Zhou, T.; Cao, J. Thymol Increases Sensitivity of Clinical Col-R Gram-Negative Bacteria to Colistin. *Microbiol. Spectr.* 2022, 10, e0018422. [CrossRef] [PubMed]

36. Kulkarni, S.A.; Nagarajan, S.K.; Ramesh, V.; Palaniyandi, V.; Selvam, S.P.; Madhavan, T. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein. *J. Mol. Struct.* 2020, 1221, 128823. [CrossRef]

37. Hassan, H.F.H.; Mansour, A.M.; Salama, S.A.; El-Sayed, E.M. The chemopreventive effect of thymol against dimethylhydrazine and/or high fat diet-induced colon cancer in rats: Relevance to NF-κB. *Life Sci.* 2021, 274, 119335. [CrossRef]

38. Mendes, S.S.; Bomfim, R.R.; Jesus, H.C.; Alves, P.B.; Blank, A.F.; Estevam, C.S.; Antoniolli, A.R.; Thomazzi, S.M. Evaluation of the analgesic and anti-inflammatory effects of the essential oil of *Lippia gracilis* leaves. *J. Ethnopharmacol.* 2010, 129, 391–397. [CrossRef]

39. Mohammadi, A.; Mahjoub, S.; Ghafarzadegan, K.; Nouri, H.R. Immunomodulatory effects of Thymol through modulation of redox status and trace element content in experimental model of asthma. *Biomed. Pharmacother.* 2018, 105, 856–861. [CrossRef]

40. Raghuvanshi, D.S.; Verma, N.; Singh, S.V.; Khare, S.; Pal, A.; Negi, A.S. Synthesis of thymol-based pyrazolines: An effort to perceive novel potent-antimalarials. *Biog. Chem.* 2019, 88, 102933. [CrossRef]

41. Robledo, N.; Vera, P.; Lopez, L.; Yazdani-Pedram, M.; Tapia, C.; Abugoch, L. Thymol nanoemulsions incorporated in quinoa protein/chitosan edible films; antifungal effect in cherry tomatoes. *Food Chem.* 2018, 246, 211–219. [CrossRef] [PubMed]

42. Franzosa, E.A.; Sirota-Madi, A.; Avila-Pacheco, J.; Fornelos, N.; Haiser, H.J.; Reinker, S.; Vatanen, T.; Hall, A.B.; Mallick, H.; McIver, L.J.; et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nat. Microbiol.* 2019, 4, 293–305. [CrossRef]

43. Wei, H.K.; Xue, H.X.; Zhou, Z.X.; Peng, J. A carvacrol-thymol blend decreased intestinal oxidative stress and influenced selected microbes without changing the messenger RNA levels of tight junction proteins in jejunal mucosa of weaning pigs. *Animal* 2017, 11, 193–201. [CrossRef] [PubMed]

44. Mueller, K.; Blum, N.M.; Mueller, A.S. Examination of the Anti-Inflammatory, Antioxidant, and Xenobiotic-Inducing Potential of Broccoli Extract and Various Essential Oils during a Mild DSS-Induced Colitis in Rats. *ISRN Gastroenterol.* 2013, 2013, 710856. [CrossRef] [PubMed]

45. Wang, Y.; Yang, Z.; Zhou, Y.; Tan, J.; Sun, H.; Sun, D.; Mu, Y.; Peng, J.; Wei, H. Effects of different amino acid levels and a carvacrol-thymol blend on growth performance and intestinal health of weaned pigs. *J. Anim. Sci. Biotechnol.* 2022, 13, 22. [CrossRef] [PubMed]

46. Fernández-Tomé, S.; Ortega Moreno, L.; Chaparro, M.; Gisbert, J.P. Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease. *Int. J. Mol. Sci.* 2021, 22, 10224. [CrossRef] [PubMed]

47. Ribeiro, A.R.S.; Diniz, P.B.F.; Pinheiro, M.S.; Albuquerque-Junior, R.L.C.; Thomazzi, S.M. Gastroprotective effects of thymol on gastric and duodenal ulcers in rats: The role of prostaglandins, ATP-sensitive K+ channels, and gastric mucus secretion. *Chem. Biol. Interact.* 2016, 244, 121–128. [CrossRef]

48. Omonijo, F.A.; Liu, S.; Hui, Q.; Zhang, H.; Lahaye, L.; Bodin, J.C.; Gong, J.; Nyachoti, M.; Yang, C. Thymol Improves Barrier Function and Attenuates Inflammatory Responses in Porcine Intestinal Epithelial Cells during Lipopolysaccharide (LPS)-Induced Inflammation. *J. Agric. Food Chem.* 2019, 67, 615–624. [CrossRef]

49. Putaala, H.; Nurminen, P.; Tiitonen, K. Effects of cinnamaldehyde and thymol on cytotoxicity, tight junction barrier resistance, and cyclooxygenase-1 and -2 expression in Caco-2 cells. *J. Anim. Sci.* 2017, 66, 274–284. [CrossRef]

50. Yin, D.; Du, E.; Yuan, J.; Gao, J.; Wang, Y.; Aggrey, S.E.; Guo, Y. Supplemental thymol and carvacrol increases ileum Lactobacillus population and reduces effect of necrotic enteritis caused by Clostridium perfringes in chickens. *Sci. Rep.* 2017, 7, 7334. [CrossRef]

51. Choy, M.C.; Visvanathan, K.; Cruz, P.D. An Overview of the Innate and Adaptive Immune System in Inflammatory Bowel Disease. *Inflamm. Bowel Dis.* 2017, 23, 2–13. [CrossRef] [PubMed]

52. Iliev, I.D.; Funari, V.A.; Taylor, K.D.; Nguyen, Q.; Reyes, C.N.; Strom, S.P.; Brown, J.; Becker, C.A.; Fleshner, P.R.; Dubinsky, M.; et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science* 2012, 336, 1314–1317. [CrossRef] [PubMed]
53. Roy, U.; Galvez, E.J.C.; Iljazovic, A.; Lesker, T.R.; Blażejewski, A.J.; Pils, M.C.; Heise, U.; Huber, S.; Flavell, R.A.; Strowig, T. Distinct Microbial Cells Trigger Collitis Development upon Intestinal Barrier Damage via Innate or Adaptive Immune Cells. *Cell. Rep.* 2017, 21, 994–1008. [CrossRef] [PubMed]

54. Natarajan, K.; Abraham, P.; Kota, R.; Isaac, B. NF-κB-iNOS-COX2-TNF-α inflammatory signaling pathway plays an important role in methotrexate induced small intestinal injury in rats. *Food. Chem. Toxicol.* 2018, 118, 766–783. [CrossRef]

55. Salim, S.Y.; Söderholm, J.D. Importance of disrupted intestinal barrier in inflammatory bowel diseases. *Inflamm. Bowel Dis.* 2011, 17, 362–381. [CrossRef]

56. Chauhan, A.K.; Kang, S.C. Thymol disrupts the membrane integrity of Salmonella ser. typhimurium in vitro and recovers infected macrophages from oxidative stress in an ex vivo model. *Res. Microbiol.* 2014, 165, 559–565. [CrossRef]

57. Peng, Y.; Zhang, X.; Zhang, T.; Grace, P.M.; Li, H.; Wang, Y.; Li, H.; Chen, H.; Watkins, L.R.; Hutchinson, M.R.; et al. Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain. *Brain Behav. Immun.* 2019, 82, 432–444. [CrossRef]

58. Khazdair, M.R.; Ghorani, V.; Alavinezhad, A.; Boskabady, M.H. Pharmacological effects of Zataria multiflora Boiss L. and its constituents focus on their anti-inflammatory, antioxidative, and immunomodulatory effects. *Fundam. Clin. Pharmacol.* 2018, 32, 26–50. [CrossRef]

59. Gholijani, N.; Gharagozloo, M.; Farjadian, S.; Amirghofran, Z. Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophages. *J. Immunotoxicol.* 2016, 13, 157–164. [CrossRef]

60. Jin, B.R.; Chung, K.S.; Cheon, S.Y.; Lee, M.; Hwang, S.; Noh Hwang, S.; Rhee, K.J.; An, H.J. Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation. *Sci. Rep.* 2017, 7, 46252. [CrossRef]

61. Chamana, M.; Abdollahi, A.; Rezayat, S.M.; Ghazi-Khansari, M.; Dehpour, A.; Nassireslami, E.; Rashidian, A. Thymol reduces acetic acid-induced inflammatory response through inhibition of NF-κB signalling pathway in rat colonic tissue. *Inflammopharmacology* 2019, 27, 1275–1283. [CrossRef] [PubMed]

62. Liu, D.-M.; Zhou, C.-Y.; Meng, X.-L.; Wang, P.; Li, W. Thymol exerts anti-inflammatory effect in dextran sulfate sodium-induced experimental murine colitis. *Trop. J. Pharm. Res.* 2018, 17, 1803–1810. [CrossRef]

63. Tahmasebi, P.; Abtahi Froushani, S.M.; Afzale Ahangaran, N. Thymol has beneficial effects on the experimental model of ulcerative colitis. *Arzneim. Forsch.* 2019, 69, 538–550. [CrossRef]

64. Liang, D.; Li, F.; Fu, Y.; Cao, Y.; Song, X.; Wang, T.; Wang, W.; Guo, M.; Zhou, E.; Li, D.; et al. Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-κB and MAPK signalling pathways in mouse mammary epithelial cells. *Inflammation* 2014, 37, 214–222. [CrossRef] [PubMed]

65. Wang, Q.; Cheng, F.; Xu, Y.; Zhang, J.; Qi, J.; Liu, X.; Wang, R. Thymol alleviates lipopolysaccharide-stimulated inflammatory response via downregulation of RhoA-mediated NF-κB signalling pathway in human peritoneal mesothelial cells. *Eur. J. Pharmocol.* 2018, 833, 210–220. [CrossRef] [PubMed]

66. Nagooz Meeran, M.F.; Jagadeesh, G.S.; Selvaraj, P. Thymol attenuates inflammation in isoproterenol induced myocardial infarcted rats by inhibiting the release of lysosomal enzymes and downregulating the expressions of proinflammatory cytokines. *Eur. J. Pharmocol.* 2015, 754, 153–161. [CrossRef] [PubMed]

67. Khosravi, A.R.; Erle, D.J. Chitin-Induced Airway Epithelial Cell Innate Immune Responses Are Inhibited by Carvacrol/Thymol. *PloS ONE* 2016, 11, e0159459. [CrossRef]

68. Kwon, H.I.; Jeong, N.H.; Kim, S.Y.; Kim, M.H.; Son, J.H.; Jun, S.H.; Kim, S.; Jeon, H.; Kang, S.C.; Kim, S.H.; et al. Inhibitory effects of thymol on the cytotoxicity and inflammatory responses induced by Staphylococcus aureus extracellular vesicles in cultured keratinocytes. *Microb. Pathog.* 2019, 134, 103603. [CrossRef]

69. Koc, K.; Ceric, S.; Ucar, S.; Colak, S.; Bakir, M.; Erol, H.S.; Yildirim, S.; Hosseinigouzadagani, M.; Simsek Ozbek, N.; Aysin, F.; et al. Autophagic and Proinflammatory effects of oleuropein and thymol on indomethacin-induced gastric ulcer in Sprague-Dawley rats. *Brain Behav. Immun.* 2019, 82, 540–551. [CrossRef] [PubMed]

70. Kilic, K.; Sakat, M.S.; Yildirim, S.; Kandemir, F.M.; Gozeler, M.S.; Dortbudak, M.B.; Kucukler, S. The amnesticatory effect of hesperidin and thymol in allergic rhinitis: An ovalbumin-induced rat model. *Eur. Arch. Otorhinolaryngol.* 2019, 276, 407–415. [CrossRef] [PubMed]

71. Waetzig, G.H.; Seegert, D.; Rosenstiel, P.; Nikolaus, S.; Schreiber, S. p38 Mitogen-Activated Protein Kinase Is Activated and Linked to TNF-α Signaling in Inflammatory Bowel Disease. *J. Immunol.* 2002, 168, 5342–5351. [CrossRef] [PubMed]

72. Chen, J.; Li, D.-L.; Xie, L.-N.; Ma, Y.-R.; Wu, P.-P.; Li, C.; Liu, W.-F.; Zhang, K.; Zhou, R.-P.; Xu, X.-T.; et al. Synergistic anti-inflammatory effects of silibinin and thymol combination on LPS-induced RAW264.7 cells by inhibition of NF-κB and MAPK activation. *Phytomedicine* 2020, 78, 15309. [CrossRef]

73. Tanaka, A.; Sakaguchi, S. Regulatory T cells in cancer immunotherapy. *Cell Res.* 2017, 27, 109–118. [CrossRef] [PubMed]

74. Nair, G.; Izad, M.; Rezaei, F.; Amirghofran, Z. Thymol as a reciprocal regulator of T cell differentiation: Promotion of regulatory T cells and suppression of Th1/Th17 cells. *Int. Immunopharmacol.* 2019, 67, 417–426. [CrossRef]

75. Gholijani, N.; Amirghofran, Z. Effects of thymol and carvacrol on T-helper cell subset cytokines and their main transcription factors in ovalbumin-immunized mice. *J. Immunotoxicol.* 2016, 13, 729–737. [CrossRef]

76. Amirghofran, Z.; Ahmadi, H.; Karimi, M.H.; Kalantar, F.; Gholijani, N.; Malek-Hosseini, Z. In vitro inhibitory effects of thymol and carvacrol on dendritic cell differentiation and function. *Pharm. Biol.* 2016, 54, 1125–1132.
Antioxidants 2022, 11, 1947

77. Tian, T.; Wang, Z.; Zhang, J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid. Med. Cell. Longev. 2017, 2017, 4335194. [CrossRef] [PubMed]

78. Zhang, J.; Wang, X.; Vikash, Y.; Ye, Q.; Wu, D.; Liu, Y.; Dong, W. ROS and ROS-Mediated Cellular Signaling. Oxid. Med. Cell. Longev. 2016, 2016, 4350965. [CrossRef] [PubMed]

79. Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, R453–R462. [CrossRef] [PubMed]

80. Yan, H.; Jin, J.Q.; Yang, P.; Yu, B.; He, J.; Mao, X.B.; Yu, J.; Chen, D.W. Fermented soybean meal increases nutrient digestibility via the improvement of intestinal function, anti-oxygen protective function of weaned pigs. Animal 2022, 16, 100537. [CrossRef]

81. Yao, J.; Wang, J.Y.; Liu, L.; Li, Y.X.; Xun, A.Y.; Zeng, W.S.; Jia, C.H.; Wei, X.X.; Feng, J.L.; Zhao, L.; et al. Anti-oxidant effects of resveratrol on mice with DSS-induced ulcerative colitis. Arch. Med. Res. 2010, 41, 288–294. [CrossRef] [PubMed]

82. Gavaric, N.; Mozina, S.S.; Kladar, N.; Bozin, B. Chemical Profile, Antioxidant and Antibacterial Activity of Thyme and Oregano Essential Oils, Thymol and Carvacrol and Their Possible Synergism. J. Essent. Oil Bear. Plants. 2015, 18, 1013–1021. [CrossRef]

83. Yu, Y.-M.; Chao, T.-Y.; Chang, W.-C.; Chang, M.I.; Lee, M.-F. Thymol reduces oxidative stress, aortic intimal thickening, and inflammation-related gene expression in hyperlipidemic rabbits. J. Food Drug Anal. 2016, 24, 556–563. [CrossRef] [PubMed]

84. Hollman, P.C.; Cassidy, A.; Comte, B.; Heinonen, M.; Richling, E.; Serafini, M.; Scalbert, A.; Sies, H.; Vidry, S. The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J. Nutr. 2011, 141, 9895–9909S. [CrossRef]

85. Croft, K.D. Dietary polyphenols: Antioxidants or not? Arch. Biochem. Biophys. 2016, 585, 120–124. [CrossRef]

86. FangFang; Li, H.; Qin, T.; Li, M.; Ma, S. Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway. Metab. Brain Dis. 2017, 32, 385–393. [CrossRef]

87. Yao, L.; Hou, G.; Wang, L.; Zuo, X.S.; Liu, Z. Protective effects of thymol on LPS-induced acute lung injury in mice. Microb. Pathog. 2018, 116, 8–12. [CrossRef]

88. Bainbridge, S.A.; Smith, G.N. HO in pregnancy. Free Radic. Biol. Med. 2005, 38, 979–988. [CrossRef]

89. El-Nekeety, A.A.; Mohamed, S.R.; Hathout, A.S.; Hassan, N.S.; Aly, S.E.; Abdel-Wahhab, M.A. Antioxidant properties of Thymus vulgaris oil against aflatoxin-induced oxidative stress in male rats. Toxicol 2011, 57, 984–991. [CrossRef]

90. Archana, P.R.; Nageshwar Rao, B.; Ballal, M.; Satish Rao, B.S. Thymol, a naturally occurring monocyclic dietary phenolic compound protects Chinese hamster lung fibroblasts from radiation-induced cytotoxicity. Mutat. Res. 2009, 680, 70–77. [CrossRef]

91. Archana, P.R.; Nageshwar Rao, B.; Satish Rao, B.S. Modulation of gamma ray-induced genotoxic effect by thymol, a monoterpene phenol derivative of cymene. Integ. Cancer Ther. 2011, 10, 374–383. [CrossRef] [PubMed]

92. Khan, A.; Ahmad, A.; Ahmad Khan, L.; Padoa, C.J.; van Vuuren, S.; Manzoor, N. Effect of two monoterpene phenols on antioxidant defense system in Candida albicans. Microb. Pathog. 2015, 58, 50–56. [CrossRef] [PubMed]

93. Saber, T.M.; Arisha, A.H.; Abo-Elmaaty, A.M.A.; Abdelgawad, F.E.; Metwally, M.M.M.; Saber, T.; Mansour, M.F. Thymol alleviates imidacloprid-induced testicular toxicity by modulating oxidative stress and expression of steroidogenesis and apoptosis-related genes in adult male rats. Ecotoxicol. Environ. Saf. 2021, 221, 112435. [CrossRef] [PubMed]

94. Stojanović, N.M.; Mitić, K.V.; Randjelevo, P.; Stevanović, M.; Stojilković, N.; Ilić, S.; Trčković-Vukić, D.; Sokolović, D.; Jevtić-Stoimenov, T.; Radulović, N.S. Thymol regulates the functions of immune cells in the rat peritoneal cavity after l-arginine-induced pancreatitis. Life Sci. 2021, 280, 119704. [CrossRef]

95. Haque, M.R.; Ansari, S.H.; Najmi, A.K.; Ahmad, M.A. Monoterpene phenolic compound thymol prevents high fat diet induced obesity in murine model. Toxicol. Mech. Methods 2014, 24, 116–123. [CrossRef]

96. Youdim, K.; Deans, S.G. Effect of thyme oil and thyme dietary supplementation on the antioxidant status and fatty acid composition of the ageing rat brain. Br. J. Nutr. 2000, 83, 87–93. [CrossRef]

97. Güvenç, M.; Cellat, M.; Gökçek, İ.; Yavaş, İ.; Yurdagül Özsoy, Ş. Effects of thymol and carvacrol on sperm quality and oxidant/antioxidant balance in rats. Arch. Physiol. Biochem. 2019, 125, 396–403. [CrossRef]

98. El-Sayed, E.M.; Abd-Allah, A.R.; Mansour, A.M.; Abdel-Arabey, A.A. Thymol and carvacrol prevent cisplatin-induced nephrotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats. J. Biochem. Mol. Toxicol. 2015, 29, 165–172.

99. Palabiyik, S.S.; Karakus, E.; Halici, Z.; Cadirci, E.; Bayir, Y.; Ayaz, G.; Cinar, I. The protective effects of carvacrol and thymol against paracetamol-induced toxicity on human hepatocellular carcinoma cell lines (HepG2). Hum. Exp. Toxicol. 2016, 35, 1252–1263. [CrossRef]

100. Abbasi, S.; Gharaghi, S.; Benvidi, A.; Rezaeinasa, M.; Saboury, A.A. An in-depth view of potential dual effect of thymol in inhibiting xanthine oxidase activity: Electrochemical measurements in combination with four way PARAFAC analysis and molecular docking insights. Int. J. Biol. Macromol. 2018, 119, 1298–1310. [CrossRef]

101. Kostić, D.A.; Dimitrijević, D.S.; Stojanović, G.S.; Palić, I.R.; Đorđević, A.S.; Ickovski, J.D. Xanthine Oxidase: Isolation, Assays of Activity, and Inhibition. J. Chem. 2015, 2015, 294858. [CrossRef] [PubMed]

102. Rehman, A.; Rausch, P.; Wang, J.; Skeieceviciene, J.; Kuodelis, G.; Bhagalia, K.; Amarpurkar, D.; Kupcinskas, L.; Schreiber, S.; Rosenstiel, P.; et al. Geographical patterns of the standing and active human gut microbiome in health and IBD. Gut 2016, 65, 238–248. [CrossRef] [PubMed]

103. Ni, J.; Wu, G.D.; Albenberg, L.; Tomov, V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573–584. [CrossRef] [PubMed]
104. Liu, S.; Zhao, W.; Lan, P.; Mou, X. The microbiome in inflammatory bowel diseases: From pathogenesis to therapy. *Protein Cell* 2021, 12, 331–345. [CrossRef]

105. Manichanh, C.; Rigottier-Gois, L.; Bonnaud, E.; Gloux, K.; Pelletier, E.; Frangeul, L.; Nalin, R.; Jarrin, C.; Chardon, P.; Marteau, P.; et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut* 2006, 55, 205–211. [CrossRef] [PubMed]

106. Mo, K.; Li, J.; Liu, F.; Xu, Y.; Huang, X.; Ni, H. Superiority of Microencapsulated Essential Oils Compared With Common Essential Oils and Antibiotics: Effects on the Intestinal Health and Gut Microbiota of Weaning Piglet. *Front. Nutr.* 2021, 8, 808106. [CrossRef]

107. Du, E.; Gan, L.; Li, Z.; Wang, W.; Liu, D.; Guo, Y. In vitro antibacterial activity of thymol and carvacrol and their effects on broiler chickens challenged with *Clostridium perfringens*. *J. Anim. Sci. Biotechnol.* 2015, 6, 58. [CrossRef]

108. Chien, S.Y.; Sheen, S.; Sommers, C.H.; Sheen, L.Y. Modeling the Inactivation of Intestinal Pathogenic *Escherichia coli* O157:H7 and Uropathogenic *E. coli* in Ground Chicken by High Pressure Processing and Thymol. *Front. Microbiol.* 2016, 7, 920. [CrossRef]

109. Shah, B.; Davidson, P.M.; Zhong, Q. Nanocapsular dispersion of thymol for enhanced dispersibility and increased antimicrobial effectiveness against *Escherichia coli* O157:H7 and *Listeria monocytogenes* in model food systems. *Appl. Environ. Microbiol.* 2012, 78, 8448–8453. [CrossRef]

110. Varel, V.H.; Miller, D.N. Plant-derived oils reduce pathogens and gaseous emissions from stored cattle waste. *Appl. Environ. Microbiol.* 2001, 67, 1366–1370. [CrossRef]

111. Qiao, J.; Shang, Z.; Liu, X.; Wang, K.; Wu, Z.; Wei, Q.; Li, H. Regulatory Effects of Combined Dietary Supplementation With Essential Oils and Organic Acids on Microbial Communities of Cobb Broilers. *Front. Microbiol.* 2021, 12, 814626. [CrossRef] [PubMed]

112. Ananthakrishnan, A.N. Epidemiology and risk factors for IBD. *Nat. Rev. Gastroenterol. Hepatol.* 2015, 12, 205–217. [CrossRef] [PubMed]

113. Piovani, D.; Danese, S.; Peyrin-Biroulet, L.; Nikolopoulos, G.K.; Lytras, T.; Bonovas, S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. *Gastroenterology* 2019, 157, 647–659.e644. [CrossRef] [PubMed]

114. Wu, Z.; Huang, S.; Li, T.; Li, N.; Han, D.; Zhang, B.; Xu, Z.Z.; Zhang, S.; Pang, J.; Wang, S.; et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis. *Microbiome* 2021, 9, 184. [CrossRef]

115. Green, N.; Miller, T.; Suskind, D.; Lee, D. A Review of Dietary Therapy for IBD and a Vision for the Future. *Nutrients* 2019, 11, 947. [CrossRef]